Committed to precision medicine and personalized IBD care


Our mission at The Ohio State University Wexner Medical Center’s Inflammatory Bowel Disease Center is to practice precision medicine and develop personalized treatment plans for our patients through comprehensive, evidence-based IBD care.

We are a dedicated, multidisciplinary team that recognizes the complexity in managing and caring for IBD patients, whether it involves diet and nutrition, medical therapy or surgical intervention.

The Inflammatory Bowel Disease Center is committed to conducting clinical trials for patients who do not respond to standard therapy. Our patients have access to participate in state-of-the-art clinical trials for new drugs and technologies.

Upcoming CME events


Programs in development:

  • A pediatric-to-adult IBD transition clinic, in collaboration with Nationwide Children’s Hospital, to ensure young adults have a smooth transition to adult care at Ohio State and get all the services they need. 
  • A telehealth service allowing shared visits with clinicians and patients throughout Ohio and the surrounding region, improving access and standardizing our care centered on evidence-based, up-to-date medicine for IBD in underserved areas.
Ongoing clinical research trials

Ongoing clinical research trials

The Ohio State University Wexner medical Center is a national leader in conducting clinical trials for the prevention and treatment of various disease, including IBD. The Division of Gastroenterology, Hepatology, and Nutrition and the Inflammatory Bowel Disease Center conduct industry sponsored research studies for both Crohn’s disease and ulcerative colitis.

ADVANCE

A study enrolling moderate to severe Crohn’s disease patients that have failed one or more of the following: oral or local steroids; systemic steroids; immunomodulators; and/or biologic therapy

BLINK

Comparison of capsule endoscopy to ileocolonscopy plus MRE

Explorer

An open label, triple therapy, phase 4 study for early treatment of Crohn’s disease

GALAXI

A phase 3 study enrolling moderate to severe Crohn’s disease patients or fistulizing Crohn’s disease patients, with past colitis, ileitis, or ileocolitis

MOTIVATE

A study enrolling moderate to severe Crohn’s disease patients that have failed one or more biologic therapy

SBS Registry

A registry collecting data on patients with short bowel syndrome

U-Achieve

A study enrolling moderate to severe ulcerative colitis patients that failed one or more biologic therapy